Effects of Intragastric Balloon in Patients with Non-Alcohol
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Effective therapy for clinically significant fibrosis in non-alcoholic fatty liver disease (NAFLD) is an unmet need. The study found that regression of fibrosis can be achieved by obese patients with advanced liver fibrosis, treated with 6 months of IGB.

In this study by Liver International, investigators evaluated the impact of IGB placement in NAFLD patients with advanced fibrosis.

Researchers retrospectively assessed the effects of the fluid-filled IGB in a cohort of obese patients with liver stiffness ≥9.7 kPa (corresponding to F3-F4). Patients with endoscopic signs of portal hypertension were excluded. Changes in metabolic and liver parameters from baseline to follow-up (6 months) were assessed.

A total of 26 obese patients were included.

--All patients achieved a significant body weight loss and waist circumference reduction at 6-month follow-up after IGB placement.

--Weight loss induced by IGB lowered blood glucose, glycated hemoglobin, FIB-4, liver stiffness, and controlled attenuation parameter.

--Gastroesophageal reflux symptoms were common, but no severe adverse event was observed.

Conclusively, obese patients with advanced liver fibrosis, treated with 6-month IGB, can achieve regression of fibrosis as assessed by reduction of liver stiffness and FIB-4.

Source: https://doi.org/10.1111/liv.14917
1 share
Like
Comment
Share